Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods
* 19 weeks for the Core Phase. It is composed of:
* a Screening period: a maximum of 3 weeks
* a Run-in period (no treatment): 4 weeks
* a Blinded Treatment Phase: 12 weeks
* 36 weeks Extension Phase = an open-label Treatment period
* 4 weeks for the safety follow-up period (without any treatment).